10.1016/j.peptides.2017.02.009 411
The trial demonstrated a significant reduction of 25% in the primary composite outcome of cardiovascular death and first HFH (19.4% versus 24.7% [HR 0.75
Contraindications include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, as GLP-1 agonists have shown thyroid effects in animal models
Simic, T., Pljesa-Ercegovac, M., Savic-Radojevic, A., Hadziahmetovic, M
log [1.25])
According to clinical trials published in the New England Journal of Medicine, Zepbound shows slightly higher rates of GI effects at higher doses: nausea (31-33%), diarrhea (21-23%), and vomiting (12-20%)